IPO
Coverage Timeline
newest first- Aug 10, 2026IPOBiotech IPO Window Closes Its Strongest Week Since Spring~$972M, 4 deals→
- Aug 7, 2026IPOLatigo Biotherapeutics Jumps 17% in $345.6M IPO$345.6M IPO→
- Aug 4, 2026IPOAttovia Prices IPO as Biotech's Public Pipeline Fills Out$17/share IPO→
- Aug 4, 2026IPOLatigo Sets Terms for a $272M Nasdaq IPO$272M IPO→
- Aug 3, 2026IPOBlue Owl-Backed Latigo Advances Nasdaq IPO Plans→
All Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
IPO
Latigo Biotherapeutics Jumps 17% in $345.6M IPO
IPO$345.6M IPO
Latigo Biotherapeutics Jumps 17% in $345.6M IPO
Latigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.
FOLLOW-UP
IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
IPO
Latigo Sets Terms for a $272M Nasdaq IPO
IPO$272M IPO
Latigo Sets Terms for a $272M Nasdaq IPO
Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.
IPO
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
IPO
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.